COLLEGIUM PHARMACEUTICAL, INC 8K

Collegium Pharmaceutical reported Q2 2026 results, disclosed completion of the AZSTARYS acquisition and integration, and updated 2026 guidance by lowering total revenue and adjusted EBITDA targets while increasing AZSTARYS revenue expectations.

On August 6, 2026, Collegium Pharmaceutical, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a business update, highlighting the completed May 2026 acquisition and ongoing integration of AZSTARYS®, strong growth in its ADHD franchise (including 41% year-over-year JORNAY PM® revenue growth and $12.9 million in partial-quarter AZSTARYS revenue), a mixed but still sizable pain portfolio performance, and revised full‑year 2026 guidance that lowers expected total product revenues and adjusted EBITDA primarily due to weaker pricing on authorized generic Nucynta products while raising AZSTARYS revenue guidance and reaffirming JORNAY PM guidance; the company also outlined corporate developments including a planned headquarters move to downtown Boston in early 2027, a new board appointment, upcoming investor conference participation, and provided detailed reconciliations of non‑GAAP metrics such as adjusted EBITDA, adjusted operating expenses, and adjusted net income.

Filing Facts

CIK

1267565

Ticker

COLL

Form

8K

Source Type

fda

Accession

0001628280-26-053849

Alert Tier

7